Literature DB >> 32406512

Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection.

Gabriel Chodick1,2, Amir Nutman1,3, Naama Yiekutiel2, Varda Shalev1,2.   

Abstract

Entities:  

Keywords:  ACE2 receptor; BMI; Covid19; Israel; Vitamin D; anti-hypertensive; body mass index; hypertension; obesity

Mesh：

Substances：

Year:  2020        PMID： 32406512      PMCID： PMC7239115          DOI： 10.1093/jtm/taaa069

Source DB:  PubMed          Journal:  J Travel Med        ISSN： 1195-1982            Impact factor:   8.490


× No keyword cloud information.
  7 in total

Review 1.  Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Authors:  Jordan Loader; Frances C Taylor; Erik Lampa; Johan Sundström
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

2.  Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.

Authors:  Nanyang Liu; Jiahui Sun; Xiyuan Wang; Tingting Zhang; Ming Zhao; Hao Li
Journal:  Int J Infect Dis       Date:  2021-01-02       Impact factor: 3.623

3.  Corrigendum to: Influence of 25‑hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: A systematic review and meta-analysis [EClinicalMedicine 37 (2021) 100,967].

Authors:  Andrea Crafa; Rossella Cannarella; Rosita A Condorelli; Laura M Mongioì; Federica Barbagallo; Antonio Aversa; Sandro La Vignera; Aldo E Calogero
Journal:  EClinicalMedicine       Date:  2021-10-20

4.  Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.

Authors:  Alexander T Sandhu; Shun Kohsaka; Shoutzu Lin; Christopher Y Woo; Mary K Goldstein; Paul A Heidenreich
Journal:  Am Heart J       Date:  2021-06-12       Impact factor: 4.749

5.  Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: A systematic review and meta-analysis.

Authors:  Andrea Crafa; Rossella Cannarella; Rosita A Condorelli; Laura M Mongioì; Federica Barbagallo; Antonio Aversa; Sandro La Vignera; Aldo E Calogero
Journal:  EClinicalMedicine       Date:  2021-06-18

6.  A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?

Authors:  Amanj Kurdi; Nouf Abutheraa; Lina Akil; Brian Godman
Journal:  Pharmacol Res Perspect       Date:  2020-12

7.  Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.

Authors:  Daniel Caldeira; Mariana Alves; Ryan Gouveia E Melo; Pedro Silvério António; Nélson Cunha; Afonso Nunes-Ferreira; Luisa Prada; João Costa; Fausto J Pinto
Journal:  Int J Cardiol Heart Vasc       Date:  2020-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.